iqvia glp-1 prescriptions q3 2024 semaglutide tirzepatide Are Up, Health Services Utilization Down, and GLP-1s Are a Major Growth Driver: IQVIA's Update India's obesity and diabetes market

This level of personalization allows patients with specific requirements to access medications that suit their unique conditions

Active Ingredient Tirzepatide (Advanced Dual-Agonist) Dose Strength per Injection 12.5 mg per single weekly 0.6mL dose Total Content per KwikPen 50 mg Tirzepatide in 2.4 mL solution Primary Manufacturer Eli Lilly and Company Therapeutic Class GIP / GLP-1 Receptor Agonist (Anti-Obesity / Antidiabetic) Administration Route Subcutaneous Injection (Weekly advanced baseline) Supply Timeline 1 Pre-filled Pen (4-week advanced course)

The peptide calculator helps with dose calculations regardless of which delivery method you choose

Thanks for helping with my weight loss journey

Here is what each group received: 1mg group: 1mg weekly for the full 48 weeks, no escalation 4mg (starting at 2mg): Started at 2mg, escalated to 4mg after 4 weeks 4mg (starting at 4mg): Started directly at 4mg, no escalation 8mg (starting at 2mg): Started at 2mg, escalated through 4mg to reach 8mg 8mg (starting at 4mg): Started at 4mg, escalated to 8mg after 4 weeks 12mg (starting at 2mg): Started at 2mg, escalated through 4mg, 8mg to reach 12mg The weight loss results at 48 weeks told a clear story

Semaglutide and Tirzepatide will help with appetite control, but its still important to pay attention to whats on your plate